Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
LifeScan emerges from chapter 11
We advised an ad hoc group of secured lenders in connection with LifeScan’s chapter 11 proceedings
Sevita $1.275 billion notes offering
We advised the representative of the initial purchasers on the offering
Terns Pharmaceuticals $747.5 million stock offering
We advised the underwriters on the public offering
Biocytogen RMB1.27 billion Shanghai IPO
We advised Biocytogen on its IPO and SSE listing
Denali Therapeutics $200 million stock and pre-funded warrants offering
We advised the representatives of the several underwriters on the offering
Immix Biopharma $100 million stock and pre-funded warrants offering
We advised the sole bookrunner and representative of the several underwriters on the offering
Mirum Pharmaceuticals $200 million private placement
We advised the placement agents on the transaction
Immatics $125 million follow-on offering
We advised Immatics on the offering
Merck $8 billion notes offering
We advised the underwriters on the notes offering
Aradigm $20 million Series A financing round
We advised Frist Cressey Ventures, which led the round